Terms: = Prostate cancer AND MYB, c-myb_CDS, 4602, ENSG00000118513, P10242, efg, Cmyb, c-myb AND Prognosis
4 results:
1. [High expression of mybL2 promotes progression and predicts a poor survival outcome of prostate cancer].
Yang M; Zhu X; Shen Y; He Q; Qin Y; Shao Y; Yuan L; Ye H
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Aug; 42(8):1109-1118. PubMed ID: 36073208
[TBL] [Abstract] [Full Text] [Related]
2. WHO Classification of Tumours fifth edition: evolving issues in the classification, diagnosis, and prognostication of prostate cancer.
Kench JG; Amin MB; Berney DM; Compérat EM; Cree IA; Gill AJ; Hartmann A; Menon S; Moch H; Netto GJ; Raspollini MR; Rubin MA; Tan PH; Tsuzuki T; Turjalic S; van der Kwast TH; Zhou M; Srigley JR
Histopathology; 2022 Oct; 81(4):447-458. PubMed ID: 35758185
[TBL] [Abstract] [Full Text] [Related]
3. mybL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
Li Q; Wang M; Hu Y; Zhao E; Li J; Ren L; Wang M; Xu Y; Liang Q; Zhang D; Lai Y; Liu S; Peng X; Zhu C; Ye L
Theranostics; 2021; 11(12):5794-5812. PubMed ID: 33897882
[No Abstract] [Full Text] [Related]
4. Integrative genomic analyses of the histamine H1 receptor and its role in cancer prediction.
Wang M; Wei X; Shi L; Chen B; Zhao G; Yang H
Int J Mol Med; 2014 Apr; 33(4):1019-26. PubMed ID: 24535227
[TBL] [Abstract] [Full Text] [Related]
